FDA Should Consider CFC Albuterol Phase-Out Date Beyond 2005 – Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee expresses concern about availability of albuterol HFA supply on chlorofluorocarbon phase-out date. Schering-Plough and GSK tell FDA it will take up to 18 months to expand annual production capacity to 30 mil. doses each.
You may also be interested in...
Long-Acting Beta Agonist Safety Issues Will Be Discussed By Advisory Committee
"Implications of recently available data" will be the subject of a July 13 meeting. The committee will also meet July 14 to discuss the continued need for essential use designations for asthma and chronic obstructive pulmonary disease therapies.
Long-Acting Beta Agonist Safety Issues Will Be Discussed By Advisory Committee
"Implications of recently available data" will be the subject of a July 13 meeting. The committee will also meet July 14 to discuss the continued need for essential use designations for asthma and chronic obstructive pulmonary disease therapies.
CFC-Containing Albuterol Inhalers To Be Removed By 2009
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.